Aluminum chloride does not facilitate deposition of human synthetic amyloid beta1-42 peptide in the rat ventricular system of a short-term infusion model.
Recent data have demonstrated that a 39-43 amino acid peptide called beta-amyloid peptide (Abeta), which predominantly contains 42 residues (Abeta1-42), has a strong tendency to form insoluble aggregates and that the toxic effects of Abeta are based on its aggregation. In a previous study, we reported that infusion of 100 microg of human synthetic Abeta1-42 (sAbeta1-42), which is a main component of diffuse plaques, into the lateral ventricle of the rat brain of a short-term infusion model resulted in almost complete disappearance of sAbeta1-42 aggregates from the ventricles by 28 days. In addition, aluminum is considered a potential etiological factor in Alzheimer's disease (AD). Neurotoxicity from excess brain exposure to aluminum has been documented from both clinical observations and animal experiments, although a direct relationship between aluminum and AD has yet to be clearly established. We therefore investigated the effects of sAbeta1-42 aggregates with aluminum chloride (AlCl3) in the ventricular system of the rat brain of a short-term infusion model. At either 2 or 7 days following infusion, sAbeta1-42 formed aggregates with AlCl3 that spread throughout the entire ventricular system. However, sAbeta1-42 aggregates with AlCl3 had almost disappeared from the ventricles by 28 days, resulting in similarities with respect to the time-course and the neuropathological changes observed in sAbeta1-42 aggregation without AlCl3. We herein report for the first time that considerable amounts of sAbeta1-42 aggregates with AlCl3 almost disappear from the rat ventricular system by 28 days post-infusion.
Nakagawa
Yasushi
Y
Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Japan. naka@naramed-u.ac.jp
Kawashima
Toshiro
T
Yamada
Tomomi
T
Harano
Mutsuo
M
Monji
Akira
A
Yuzuriha
Takefumi
T
Iwaki
Toru
T
D000077410:Aluminum Chloride; D017607:Aluminum Compounds / Q000008:administration & dosage*; D016229:Amyloid beta-Peptides / Q000008:administration & dosage*; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000473:pathology*; D002712:Chlorides / Q000008:administration & dosage*; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007150:Immunohistochemistry; D007276:Injections, Intraventricular; D008297:Male; D010446:Peptide Fragments / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar
D017607:Aluminum Compounds; D016229:Amyloid beta-Peptides; D002712:Chlorides; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D000077410:Aluminum Chloride